Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Alisertib (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 17 Jul 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.
- 02 Jun 2017 Results from part I (dose-escalation) and part II (dose-expansion) of the study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 18 Feb 2017 Status changed from recruiting to active, no longer recruiting.